OptiNose, Inc. provided revenue guidance for full year of 2023. The Company expects XHANCE net revenues for the full year of 2023 to be between $62.0 million to $68.0 million. In addition, the Company expects the full year 2023 XHANCE average net revenue per prescription to be approximately $200.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.17 USD | +5.41% | -2.50% | -9.30% |
05-14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.30% | 161M | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose, Inc. Provides Revenue Guidance for Full Year of 2023